Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

Inclusion Criteria:

• Participants must provide written, voluntary informed consent to participate in thestudy.

• Participants must be naive to antiretroviral treatment with HIV RNA greater than orequal to 1,000 copies/mL at screening, and in the investigator's opinion, requireantiretroviral therapy.

• Participant's vital signs, physical examination, and laboratory results must notexhibit evidence of acute illness.

• Participant has not been treated for an active acquired immune deficiency syndrome (AIDS)-defining opportunistic infection within 45 days of initiating study drug.Participants who are on stable maintenance therapy for an opportunistic infection maybe enrolled after consultation with the Sponsor.

• Participant does not require and agrees not to take any drugs that are contraindicatedor have significant pharmacokinetic interactions with study drugs during the course ofthe study. Participant agrees not to take any medication during the study, includingover-the-counter medicines, vitamins, minerals, herbal preparations, alcohol, orrecreational drugs without the knowledge and permission of the principal investigator.

• Female participants must be either postmenopausal for at least one year, surgicallysterile, or must use a non-hormonal method of birth control that is acceptable to boththe participant and investigator. All female participants must have a urine pregnancytest performed at screening visit and on Day minus 1/baseline, and results of bothtests must be negative. Female participants may not be breastfeeding.

• Participants have received no prior treatment with an HIV-1 integrase inhibitor.

Exclusion Criteria:

• Participants must not have history of an allergic reaction or significant sensitivityto the study drugs.

• Participants may not have an ongoing history of substance abuse or psychiatric illnessthat could preclude protocol adherence.

• Participant cannot have resistance to lopinavir/ritonavir, tenofovir, or emtricitabinebased on the HIV-1 drug resistance genotypic test results at the screening visit.

• Participant may not have significant medical history of concomitant illness or diseasethat would adversely affect his/her participating in the study.

• Participants may not have received any investigational drug or investigational vaccinewithin 30 days prior to study drug administration.

• Participants may not have any of the following abnormal screening results: Hemoglobin <= 8.0 grams/deciliter, absolute neutrophil count <= 750 cells/microliter, Plateletcount <= 50,000 per milliliter, alanine aminotransferase (ALT) (serum glutamic-pyruvictransaminase [SGPT]) or aspartate aminotransferase (AST) (serum glutamic oxaloacetictransaminase [SGOT]) >= 3.0 x upper limit of normal (ULN), calculated creatinineclearance < 50 milliliter/minute, hepatitis B surface antigen (HBsAg) is positive.

• The investigator considers the participant to be an unsuitable candidate for thestudy.